Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$14.87 USD

14.87
3,894,704

+1.02 (7.37%)

Updated Jul 22, 2024 03:33 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Novavax (NVAX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $108.35 in the latest trading session, marking a +0.37% move from the prior day.

CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.

Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax

by Zacks Equity Research

Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.

Company News for Sep 28, 2020

by Zacks Equity Research

Companies In The News Are: TCOM, BA, NVAX, HON.

Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day

by Zacks Equity Research

Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day

Novavax Begins Phase III Study on Coronavirus Vaccine in the UK

by Zacks Equity Research

Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Rollercoaster Market for Thursday

by Mark Vickery

The major indexes gained less than 1% in total Thursday: +0.37% on the Nasdaq, +0.30% on the S&P 500, +0.20% on the Dow and +0.02% for the Russell 2000.

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

Kinjel Shah headshot

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

by Kinjel Shah

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $110.15, moving +1.65% from the previous trading session.

Novavax Expands Coronavirus Vaccine Manufacturing Deal in India

by Zacks Equity Research

Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.

Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.

Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study

by Kinjel Shah

Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.

Implied Volatility Surging for Novavax (NVAX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Novavax to Supply Coronavirus Vaccine to Canadian Government

by Zacks Equity Research

Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.

Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates

by Zacks Equity Research

The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.

Sweta Killa headshot

5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks

by Sweta Killa

While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

by Zacks Equity Research

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVAX) Outperforming Other Medical Stocks This Year?

5 Biotech Stocks Up More Than 100% This Year So Far

by Zacks Equity Research

Here we discuss five biotech companies recording impressive growth so far in 2020.

Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa

by Zacks Equity Research

Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.